Khanna, D; Seibold, J R; Wells, A; Distler, O; Allanore, Y; Denton, C; Furst, D E (2010). Systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials, outcome measures, and future study design. Current Rheumatology Review, 6(2):138-144.
Full text not available from this repository.
View at publisher
Pulmonary involvement including interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic sclerosis (scleroderma; SSc). This article reviews the current evidence based medicine regarding available therapies for SSc-ILD ; discusses the lessons learned from recent SSc-ILD randomized controlled trials (RCTs); and proposes outcome measures and recommendations for design of future RCTs for SSc-ILD.
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine|
|Dewey Decimal Classification:||610 Medicine & health|
|Deposited On:||02 Feb 2011 15:35|
|Last Modified:||23 Nov 2012 12:51|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page